Dr. Ragan Discusses X4’s Work To Advance Disease-Modifying Therapies For Rare Genetic Diseases | Podcast

Dr. Ragan discusses X4 Pharmaceuticals, which is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently undergoing a global Phase 3 trial for WHIM Syndrome and two Phase 1b trials for Waldenstrom macroglobulinemia (WM), a type of rare lymphoma, and severe congenital neutropenia (SCN).

X4 Website: https://www.x4pharma.com

X4 Twitter: https://twitter.com/x4pharma

X4 LinkedIn: https://www.linkedin.com/company/x4-pharmaceuticals